Breaking News Instant updates and real-time market news.

AMGN

Amgen

$167.24

-0.31 (-0.19%)

16:12
10/05/16
10/05
16:12
10/05/16
16:12

Amgen to present new data on IMLYGIC, Vectibix at ESMO

Amgen announced that new data on IMLYGIC in combination with an immune checkpoint inhibitor and results from retrospective analyses on Vectibix will be presented at the European Society for Medical Oncology 2016 Congress, Oct. 7-11, 2016, in Copenhagen. IMLYGIC presentations include interim results from a Phase 2 trial evaluating IMLYGIC in combination with ipilimumab versus ipilimumab alone in patients with unresected stage IIIB-IV melanoma. Vectibix abstracts include retrospective analyses of the first-line Phase 3 PRIME and PEAK studies, evaluating the association between tumor site of origin and treatment efficacy in patients with RAS wild-type metastatic colorectal cancer.

  • 07

    Oct

  • 07

    Oct

  • 05

    Nov

  • 06

    Nov

  • 19

    Jul

AMGN Amgen
$167.24

-0.31 (-0.19%)

09/01/16
09/01/16
NO CHANGE

Amgen's sBLA for Blincyto approved by FDA
Amgen's supplemental Biologics License Application for Blincyto has been approved by the FDA to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials. The approval is based on results from the Phase 1/2 '205, an open-label, multicenter, single-arm trial, which evaluated the efficacy and safety of BLINCYTO in pediatric patients with relapsed or refractory B-cell precursor ALL. Blincyto was granted breakthrough therapy, priority review and orphan drug designations by FDA, and is now approved in the U.S. for the treatment of Ph- relapsed or refractory B-cell precursor ALL. In November 2015, BLINCYTO was granted conditional marketing authorization in the European Union for the treatment of adults with Ph- relapsed or refractory B-cell precursor ALL.
09/27/16
GSCO
09/27/16
NO CHANGE
Target $206
GSCO
Conviction Buy
Goldman surprised by Amgen's Kyprolis outcome in first-line multiple myeloma
Last night, Amgen announced Phase 3 Kypolis CLARION study did not meet the primary endpoint in first-line multiple myeloma. Goldman analyst Terence Flynn was surprised by this outcome given the prior positive superiority data for Kyprolis versus Velcade in the Phase III ENDEAVOR trial. Flynn sees risk to his Kyprolis $1B sales estimate in a first-line setting, but awaits for additional details from the call and further information regarding another ongoing Phase III trial. He expects Amgen shares to be weak on the news but said the company has additional drivers beyond Kyprolis including Repatha for high cholesterol and Erenumab for migraine with additional data expected in 2H 2016 and Q1 2017. Flynn remains Conviction Buy rated on Amgen and maintains his $206 price target.
09/27/16
PIPR
09/27/16
NO CHANGE
PIPR
Overweight
Amgen's Kyprolis in good shape despite trial miss, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Amgen's Kyprolis is still likely to be viewed as a "potent backbone, with the right drugs" after a Phase 3 study in front-line myeloma failed to reach its primary endpoint. The analyst believes the impact of the failed trial on Kyprolis use will be limited and he reiterates an Overweight rating on Amgen.
09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.

TODAY'S FREE FLY STORIES

GM

General Motors

$39.42

0.32 (0.82%)

11:43
09/23/17
09/23
11:43
09/23/17
11:43
Periodicals
GM to eliminate shift at Tennessee SUV plant on 'moderating' sales, WSJ says »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.25

0.19 (0.35%)

11:34
09/23/17
09/23
11:34
09/23/17
11:34
Periodicals
Wells Fargo hires law firm to prepare CEO for Senate appearance, Reuters says »

Wells Fargo has hired law…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 13

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

EADSY

Airbus

$23.06

-0.01 (-0.04%)

11:27
09/23/17
09/23
11:27
09/23/17
11:27
Periodicals
Airbus in talks to sell all or part of Premium Aerotec, Reuters says »

Airbus is said to be in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$102.11

0.56 (0.55%)

11:06
09/23/17
09/23
11:06
09/23/17
11:06
Hot Stocks
Quest Diagnostics 'disappointed' with proposed PAMA 2018 Medicare payment rates »

Quest Diagnostics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

IRBT

iRobot

$76.14

-3.8 (-4.75%)

10:58
09/23/17
09/23
10:58
09/23/17
10:58
Periodicals
iRobot suffering after onslaught of SharkNinja cheaper models, Barron's says »

In a follow up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$69.33

0.42 (0.61%)

, SNPS

Synopsys

$80.36

0.3 (0.37%)

10:47
09/23/17
09/23
10:47
09/23/17
10:47
Periodicals
Xilinx, Synopsys are 'rising stars' amid natural evolution of AI, Barron's says »

As everyday items get…

XLNX

Xilinx

$69.33

0.42 (0.61%)

SNPS

Synopsys

$80.36

0.3 (0.37%)

CDNS

Cadence Design

$38.88

0.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UTX

United Technologies

$115.01

0.51 (0.45%)

, COL

Rockwell Collins

$130.48

0.09 (0.07%)

10:42
09/23/17
09/23
10:42
09/23/17
10:42
Periodicals
Major aircraft makers, suppliers face off, Barron's says »

While United Technologies…

UTX

United Technologies

$115.01

0.51 (0.45%)

COL

Rockwell Collins

$130.48

0.09 (0.07%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

GPRO

GoPro

$10.75

-0.19 (-1.74%)

10:33
09/23/17
09/23
10:33
09/23/17
10:33
Periodicals
Key events may create 'short squeeze' in GoPro stock, Barron's says »

GoPro, a heavily shorted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.91

0.18 (0.61%)

, RACE

Ferrari

$113.47

-0.1 (-0.09%)

10:17
09/23/17
09/23
10:17
09/23/17
10:17
Periodicals
Honda $200,000 Acura NSX lacks Ferrari 'raw appeal,' Barron's says »

Acura, Honda's (HMC)…

HMC

Honda

$29.91

0.18 (0.61%)

RACE

Ferrari

$113.47

-0.1 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.16

0.19 (0.40%)

10:07
09/23/17
09/23
10:07
09/23/17
10:07
Periodicals
Oracle shares could return 20% in a year, Barron's says »

Oracle is a latecomer to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$58.96

1.14 (1.97%)

09:59
09/23/17
09/23
09:59
09/23/17
09:59
Periodicals
Six Flags may have peaked, Barron's says »

Investors have had an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51
Periodicals
Gene therapy may be nearing 'major breakthrough,' Baron's says »

Gene therapy is rapidly…

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

AET

Aetna

$153.57

0.18 (0.12%)

, ANTM

Anthem

$182.86

-0.64 (-0.35%)

09:25
09/23/17
09/23
09:25
09/23/17
09:25
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CNC

Centene

$92.22

1.48 (1.63%)

CI

Cigna

$182.74

0.61 (0.33%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

WCG

WellCare

$167.16

1.1 (0.66%)

AOBC

American Outdoor Brands

$15.01

-0.15 (-0.99%)

RGR

Sturm, Ruger

$51.00

-1.85 (-3.50%)

WMT

Wal-Mart

$79.53

-0.48 (-0.60%)

PEP

PepsiCo

$111.85

-0.95 (-0.84%)

TGT

Target

$58.99

0.66 (1.13%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

MSFT

Microsoft

$74.41

0.2 (0.27%)

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

TWTR

Twitter

$17.61

0.03 (0.17%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 22

    Oct

  • 24

    Oct

  • 08

    Nov

  • 16

    Nov

  • 21

    Nov

  • 29

    Nov

  • 20

    Feb

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

INSE

Inspired Entertainment

$13.60

0.3 (2.26%)

17:38
09/22/17
09/22
17:38
09/22/17
17:38
Hot Stocks
Inspired Entertainment COO Wilson leaving by reason of redundancy »

On September 21, Inspired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MNOV

MediciNova

$6.18

0.3 (5.10%)

17:30
09/22/17
09/22
17:30
09/22/17
17:30
Syndicate
Breaking Syndicate news story on MediciNova »

MediciNova files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ISRG

Intuitive Surgical

$1,031.52

1.31 (0.13%)

17:25
09/22/17
09/22
17:25
09/22/17
17:25
Conference/Events
Intuitive Surgical to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

GD

General Dynamics

$205.41

-0.31 (-0.15%)

17:21
09/22/17
09/22
17:21
09/22/17
17:21
Hot Stocks
General Dynamics Electric Boat awarded $341.2M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRS

Coherus Biosciences

$12.85

0.3 (2.39%)

17:19
09/22/17
09/22
17:19
09/22/17
17:19
Syndicate
Breaking Syndicate news story on Coherus Biosciences »

Coherus Biosciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FIBK

First Interstate

$36.90

0.3 (0.82%)

17:18
09/22/17
09/22
17:18
09/22/17
17:18
Syndicate
First Interstate files to sell $250M of Class A common stock »

The shelf registration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

, NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

17:08
09/22/17
09/22
17:08
09/22/17
17:08
Hot Stocks
National Research launches metric to measure healthcare consumer loyalty »

NRC Health launched the…

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$51.79

-0.16 (-0.31%)

, HON

Honeywell

$141.75

0.89 (0.63%)

16:58
09/22/17
09/22
16:58
09/22/17
16:58
Hot Stocks
Chemours files appeal concerning SNAP 20 rule to regulate HFCs »

The Chemours Company (CC)…

CC

Chemours

$51.79

-0.16 (-0.31%)

HON

Honeywell

$141.75

0.89 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.